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Abstract
Background: In sub-Saharan Africa, chronic kidney disease (CKD) is being recognized as a non-communicable
disease (NCD) with high morbidity and mortality. In countries like Tanzania, people access many sources, including
traditional medicines, to meet their healthcare needs for NCDs, but little is known about traditional medicine
practices among people with CKD. Therefore, we sought to characterize these practices among community
members with CKD in northern Tanzania.
Methods: Between December 2013 and June 2014, we administered a previously-developed survey to a random
sample of adult community-members from the Kilimanjaro Region; the survey was designed to measure traditional
medicine practices such as types, frequencies, reasons, and modes. Participants were also tested for CKD, diabetes,
hypertension, and HIV as part of the CKD-AFRiKA study. To identify traditional medicines used in the local treatment
of kidney disease, we reviewed the qualitative sessions which had previously been conducted with key informants.
Results: We enrolled 481 adults of whom 57 (11.9 %) had CKD. The prevalence of traditional medicine use among
adults with CKD was 70.3 % (95 % CI 50.0–84.9 %), and among those at risk for CKD (n = 147; 30.6 %), it was 49.0 %
(95 % CI 33.1–65.0 %). Among adults with CKD, the prevalence of concurrent use of traditional medicine and
biomedicine was 33.2 % (11.4–65.6 %). Symptomatic ailments (66.7 %; 95 % CI 17.3–54.3), malaria/febrile illnesses
(64.0 %; 95 % CI 44.1–79.9), and chronic diseases (49.6 %; 95 % CI 28.6–70.6) were the most prevalent uses for
traditional medicines. We identified five plant–based traditional medicines used for the treatment of kidney disease:
Aloe vera, Commifora africana, Cymbopogon citrullus, Persea americana, and Zanthoxylum chalybeum.
Conclusions: The prevalence of traditional medicine use is high among adults with and at risk for CKD in northern
Tanzania where they use them for a variety of conditions including other NCDs. Additionally, many of these same
people access biomedicine and traditional medicines concurrently. The traditional medicines used for the local
treatment of kidney disease have a variety of activities, and people with CKD may be particularly vulnerable to
adverse effects. Recognizing these traditional medicine practices will be important in shaping CKD treatment
programs and public health policies aimed at addressing CKD.
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Background
Non-communicable diseases (NCDs) are a growing bur-
den in sub-Saharan Africa with significant and dispro-
portionate morbidity and mortality [1,2]. Among the
NCDs in sub-Saharan Africa, chronic kidney disease
(CKD) is being recognized as a disease with a high
prevalence and high morbidity and mortality [3]. In
Tanzania, the prevalence is estimated to be 7 % of the
population with as many as 15 % of adults in urban set-
tings living with CKD, and despite this high prevalence,
awareness is low [4].
In Tanzania, people access a variety of resources to
meet their healthcare needs, and at least 60 % of the
population is estimated to use traditional medicines
(TMs) [5]. TMs are used for numerous conditions and
ailments including NCDs; however, their use among
community members with CKD is not well-known. In
similar sub-Saharan African settings, TMs have been as-
sociated with acute and chronic kidney injury, and their
use may positively or negatively impact the effectiveness
of interventions geared toward CKD [5–7]. As such,
characterization of TM use and practices is an important
step in formulating disease management programs as
well as informing optimal public health efforts aimed at
addressing the significant regional CKD burden.
The Comprehensive Kidney Disease Assessment for
Risk Factors, epidemiology, Knowledge, and Attitudes
(CKD-AFRiKA) study is an ongoing project in northern
Tanzania with the goal of understanding the epidemi-
ology, etiology, knowledge, attitudes and practices asso-
ciated with CKD as well as other related NCDs. As part
of the study, we conducted assessments that included
focus group discussions (FGDs), in-depth interviews,
and the administration of a structured survey to
community-based adults. Our overall objective was to
characterize TM use among a community-based popula-
tion so that we may better inform local biomedical
healthcare practices and help shape public health efforts
that are sensitive to TM practices. Our specific aims
were to explore the practices, including types, frequen-
cies, reasons, and modes of TMs used, among
community-members with and at risk for CKD.
Methods
Ethics, consent, and permissions
The study protocol was approved by Duke University In-
stitutional Review Board (#Pro00040784), the Kilimanjaro
Christian Medical College (KCMC) Ethics Committee
(EC#502), and the National Institute for Medical Research
in Tanzania. The consent forms were administered ver-
bally to all participants, and written informed consent (by
signature or thumbprint) was obtained from all
participants.
Study setting
The CKD AFRIKA Study was conducted between De-
cember 2013 and June 2014 in the Kilimanjaro Region
of Tanzania. The region has an adult population of
900,000 many of whom (35 %) live in an urban setting.
The HIV prevalence is 3–5 %. The unemployment rate
is 19 %, and the majority of adults have a primary educa-
tion or less (77 %). The largest ethnic group is the
Chagga tribe followed by the Pare, Sambaa, and Maasai
tribes [8]. Swahili is the major language, and all partici-
pants in our study spoke it as their first language.
Quantitative data collection
We developed a structured survey instrument designed
to test different factors related to TM practices among
community members (Additional file 1: Appendix 1).
The development of this survey has been described else-
where, but in brief, the instrument was drafted by local
and non-local experts from multiple disciplines includ-
ing medicine, epidemiology, sociology, anthropology,
and public health. It was independently translated into
Swahili by two native speakers, and we conducted joint
reviews of each version with a focus on the codability of
words and concepts with difficult translations. To ensure
the content validity of the survey instrument, we piloted
it through multiple qualitative sessions. This was an it-
erative process that involved several adjustments to the
instrument as new themes and ideas emerged through-
out the sessions. Many of the survey items and response
categories were added directly based on the results of
these qualitative piloting sessions [5]. In its final form,
the survey instrument included nine items. It comprised
open-ended questions related to types of TMs used by
community members as well as close-ended questions
related to frequency of use, reasons for use, modes of
use, modes of access, and conditions treated by TMs.
Using two local surveyors, we verbally administered
the survey to adult community members stratified by
urban and rural status. Using a random-number gener-
ator, we selected thirty-seven sampling areas from
twenty-nine neighborhoods within the Moshi Urban and
Moshi Rural districts. We based the random neighbor-
hood selection on probability proportional to size using
the 2012 Tanzanian National Census [8]. Within each
neighborhood the sampling area was determined using
geographic points randomly generated using Arc Global
Information Systems (ArcGIS), v10.2.2 (Environmental
Systems Research Institute, Redlands, CA). Households
were then randomly chosen based on coin-flip and die-
rolling techniques according to a pre-established proto-
col [4]. We targeted an enrollment between 15 and 25
participants per sampling area, but the overall sample
size was based on the requirements of the CKD AFRIKA
study which was designed to estimate the community
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prevalence of CKD with a precision of 5 % when ac-
counting for the cluster-design effect.
All adults living in the selected households were re-
cruited, and all Tanzanian citizens over the age of 18
were eligible for inclusion. To reduce non-response
rates, we attempted a minimum of two additional visits
on subsequent days and weekends, and using mobile
phone numbers, we located eligible participants through
multiple phone calls. Additionally, when available, we
collected demographic data including gender, age, and
occupation for the non-responders.
Qualitative data collection
As part of the CKD AFRIKA project, FGDs and in-
depth interviews were conducted in a central, easily
accessible area to the participants. The methodological
details of these sessions have been described elsewhere,
but in brief, we conducted five FGDs and 27 in-depth in-
terviews both of which included key informants from
the community including well-adults from the general
population, chronically-ill adults receiving care at the
hospital medicine clinics, adults receiving care from
traditional healers, adults purchasing TMs from herbal
vendors, traditional healers, herbal vendors, and medical
doctors [5].
Disease definitions
Participants who completed a structured survey were
also tested for CKD, diabetes, hypertension, and human
immunodeficiency virus (HIV) as part of the CKD
AFRIKA Study [4]. CKD was defined as the presence of
albuminuria (≥30 mg/dL; confirmed by repeat assess-
ment) and/or a reduction in the estimated glomerular
filtration rate (eGFR) ≤60 ml/min/1.73 m2 according to
the Modification of Diet in Renal Disease equation with-
out the race factor [9]. Hypertension was defined as a
single blood pressure measurement of greater than 160/
100 mmHg, a two-measurement average greater than
140/90 mmHg, or the ongoing use of anti-hypertensive
medications. Diabetes was defined as a hemoglobin A1c
(HbA1c) level ≥ 7.0 % or the ongoing use of anti-
hyperglycemic medications, and HIV was defined as a
positive Alere Determine HIV −1/2 assay (Alere Medical
Co. Ltd; Waltham, MA) confirmed by a Uni-Gold HIV
assay (Trinity Biotech Manufacturing Ltd; Wicklow,
Ireland), a self-reported history, or the ongoing use of
highly active anti-retroviral therapy.
We considered participants to be at risk for CKD if
they had poorly controlled diabetes, hypertension, or
HIV. We considered diabetes to be poorly controlled if
the HbA1c level was ≥7.0 % with or without biomedical
therapy; we considered hypertension to be poorly con-
trolled if the blood pressure was ≥140/90 mmHg on
two-time average or ≥160/100 mmHg on one-time
measurement. We defined poorly controlled HIV as be-
ing positive for HIV but not currently receiving biomed-
ical care.
Data analysis and management
Quantitative data were analyzed using STATAv.13
(STATA Corp., College Station, TX). The median and
inter-quartile ranges (IQR) were reported for continuous
variables. All p-values are two-sided at a 0.05 signifi-
cance level. To compare differences between groups, we
used a Chi squared test, Fisher’s Exact test, or the
Wilcoxon-Mann–Whitney rank sum test. Prevalence es-
timates were sample-balanced using age- and gender-
weights based on the 2012 urban and rural district-level
census data [8]. Prevalence ratios (PR) were estimated
using generalized linear models assuming a log link, and
separate univariable models were fitted to the outcome
for each variable including gender, age, ethnicity, educa-
tion, setting (urban or rural), occupation, and self-
reported medical histories of HIV or an NCD including
diabetes, hypertension, stroke, heart disease, or chronic
obstructive lung disease/asthma. We used Taylor Series
linearization to account for the design effect due to clus-
ter sampling. All data were collected on paper and then
electronically entered into a purpose-built Research
Electronic Data Capture (REDCap) database. All data
were verified after electronic data entry by an independ-
ent reviewer to ensure accuracy.
To identify traditional medicines used for the treatment
of kidney disease, two authors (JWS and JL) independently
reviewed the transcripts of the FGDs and in-depth inter-
views conducted as part of the CKD AFRIKA Study. All
traditional medicines referenced by participants were re-
corded in the coding index, and analytic memos were cre-
ated for traditional medicines referenced as part of
treatment for kidney diseases. A third author (JO) familiar
with local languages, dialects, and customs, then cross-
referenced the local vernacular with known botanical
research catalogues in the region and country. Any dis-
crepancies were resolved by joint consensus. All of the
qualitative data, including the traditional medicine coding
index, were recorded and managed using NViVOv.10.0
(QRS International Pty Ltd, Melbourne, Australia).
Results
Demographics
We enrolled 481 adults in the CKD AFRIKA Study of
whom 57 (11.9 %) had CKD. The household non-
response rate was 15.0 % and the individual non-
response rate was 21 %. Inability to locate or contact
individuals was the most common reason for non-
response. Men (p < 0.001) and adults 18–39 years old
(p = 0.001) were more likely to be non-responders, and
the proportion of participants with a secondary or post-
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secondary education (22 %) was slightly higher than the
expected regional average (15 %) (p = 0.02).
Most of the participants with CKD were urban resi-
dents (n = 54; 95 %), female (n = 40; 70 %), ethnically
Chagga (n = 37; 65 %), had a primary school education
(n = 40; 70 %) and worked in a self-employed small busi-
ness/vendor (n = 21; 37 %) (Table 1). The median age of
CKD participants was 45 years (IQR: 35–59), and many
reported a history of hypertension (n = 25; 44 %), dia-
betes (n = 17; 30 %), heart disease (n = 6; 11 %) and HIV
(n = 6; 11 %). Few participants with CKD were aware of
their condition (n = 6; 11 %). Most adults with CKD had
a history of alcohol intake (n = 41; 72 %), and a few re-
ported a history of smoking (n = 17; 30 %). We also iden-
tified 147 (31 %) participants who did not have CKD but
were considered to be at increased risk for it. Among
these participants, 123 (84 %) had poorly controlled
hypertension, 28 (19 %) had poorly controlled diabetes,
and 8 (5.4 %) had poorly controlled HIV. Similar to
those participants with CKD (all p values > 0.05), these
high-risk participants were also mostly female (n = 102;
69 %), ethnically Chagga (n = 99; 67 %), and had a pri-
mary school level of education (n = 99; 67 %); however,
they were more likely to be rural (n = 38; 26 %) com-
pared to those with CKD (p < 0.01), and they were occu-
pied most frequently as farmers (n = 66; 45 %) (p < 0.01).
Epidemiology of traditional medicine use
TM use was high among participants with CKD. The
prevalence of TM use was 70.3 % (95 % confidence
interval [CI] 50.0-84.9 %) with most adults using TMs
1–5 times (54.4 %; 95 % CI 33.4–73.9 %) or 6–10 times
(11.7 %; 95 % CI 3.30–33.6 %) per year (Table 2). The in-
cidence of TM use of more than ten times per year was
4.30 % (95 % CI 0.01–20.7 %). Among adults with CKD,
the prevalence of concurrent TM and biomedicine use
was 33.2 % (95 % CI 11.4–65.6 %). In univariable regres-
sion, there was no significant difference in TM use by
age, gender, ethnicity, setting (urban/rural), self-reported
history of an NCD or HIV, or the ongoing use of bio-
medicines. Having obtained only a primary level of edu-
cation (PR 6.42; p = 0.07) or working in a professional
occupation (PR 3.95; p = 0.07) had the strongest associa-
tions with TM use among adults with CKD. When com-
pared to biomedicines, the prevalence of community
members with CKD reporting TMs as more effective
was 85.4 % (95 % CI 65.3–94.8), as having a lower cost
was 65.7 % (95 % CI 45.2–81.7), of being easier to access
was 58.7 % (95 % CI 39.3–75.6), as being safer was
54.9 % (95 % CI 34.3–74.0), and as being more trad-
itional or religious was 37.9 % (95 % CI 21.1–58.0).
Among those at increased risk for CKD, the preva-
lence of TM use was 49.0 % (95 % CI 33.1-65.0 %) with
most adults using TMs 1–5 times (31.0 %; 95 % CI
20.8–43.3 %) or 6–10 times (11.5 %; 95 % CI 5.50–
22.4 %) per year (Table 2). The incidence of TM use of
more than ten times per year was 7.10 % (95 % CI 3.60–
13.5 %). Among adults at risk for CKD, the prevalence
of concurrent TM and biomedicine use was 10.4 %
(95 % CI 4.70–21.6 %). In univariable regression, the on-
going use of biomedicines (PR = 1.77; p < 0.01) or having
no formal education (PR = 2.10; p = 0.08) had the stron-
gest associations with the use of TMs among adults at
risk for CKD. There was no significant difference by age,
gender, occupation, setting (urban/rural), ethnicity, or
self-reported history of an NCD or HIV.
Modes of healthcare access were varied among adult
community members with CKD. Nearly all reported
seeking healthcare advice from medical doctors (99.4 %;
95 % CI 94.8–99.9), but other sources of healthcare were
also prevalent including family and elders, traditional
healers, pharmacists, herbal vendors, and friend/neigh-
bors (Table 2). Modes of healthcare access were also var-
ied among community members without CKD, but
people with CKD were significantly more likely to report
seeking advice from traditional healers than those at low
risk (PR = 5.07; p < 0.01) or those at increased risk for
CKD (PR 4.21; p = 0.01). They also tended toward a
higher prevalence of obtaining healthcare advice from
herbal vendors compared to those at low risk (PR 2.56;
p = 0.20) or increased risk for CKD (PR 2.22; p = 0.29).
Adults with CKD reported using TMs for a variety of
conditions/diseases (Table 2). TM was most prevalent
for symptomatic ailments (66.7 %; 95 % CI 17.3–54.3),
malaria/febrile illnesses (64.0 %; 95 % CI 44.1–79.9),
chronic diseases (49.6 %; 95 % 28.6–70.6), reproductive
illnesses (45.1 %; 95 % CI 23.3–69.1), and neurologic ill-
nesses (45.1 %; 95 % CI 23.3.–69.1). Other frequent uses
included, urogenital conditions, worms/parasite treat-
ment, and spiritual/traditional reasons, and less com-
monly TMs were used for treating cancers and disease
prevention. The most common modes were mixing with
water (91.8 %; 95 % CI 82.7–96.3), drinking as a tea
(61.6 %; 95 % CI 40.8–78.9), and drinking as a soup
(59.6 %; 95 % CI 39.4–77.0). Other commons modes
were inhalation, chewing straight from the plant, drink-
ing with milk, and bathing.
Traditional medicines used for the treatment of kidney
disease in Kilimanjaro
In addition to the high prevalence of TM use among per-
sons with CKD and at high risk for CKD, we identified
many TMs in use among the general population specifically
for the treatment of kidney diseases. We recorded 168
plant-based traditional medicines referenced by participants
during the qualitative sessions. Five of these traditional
medicines were referenced directly by participants as
being used for local treatments of kidney disease:
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Aloe (Aloe vera), African Myrrh (Commifora africana),
Lemongrass (Cymbopogon citrullus), avocado (Persea
americana), and knob wood (Zanthoxylum chalybeum)
(Table 3).
Discussion
The prevalence of TM use was high among persons with
CKD and at risk for CKD in northern Tanzania. Add-
itionally, the prevalence of concurrent use of TMs and
Table 1 Participant characteristics by CKD and CKD Risk Status; CKD-AFRIKA study population, 2014; N = 481
Variable Participants
Overall (n = 481) CKD Present (n = 57) CKD Absent (n = 424) p-valuea
Low risk (n = 277) Increased risk (n = 147)
Gender 0.43
Male 123 (26 %) 17 (30 %) 61 (22 %) 45 (31 %)
Female 358 (74 %) 40 (70 %) 216 (78 %) 102 (69 %)
Age 0.39
18-39 years old 172 (36 %) 16 (28 %) 128 (46 %) 28 (19 %)
40–59 years old 191 (40 %) 24 (42 %) 112 (40 %) 55 (37 %)
60+ years old 118 (24 %) 17 (30 %) 37 (14 %) 64 (44 %)
Setting <0.01
Rural 111 (23 %) 3 (5 %) 70 (25 %) 38 (26 %)
Urban 370 (77 %) 54 (95 %) 207 (75 %) 109 (74 %)
Ethnicity 0.81
Chagga 288 (60 %) 37 (65 %) 152 (55 %) 99 (67 %)
Pare 66 (14 %) 7 (12 %) 47 (17 %) 12 (8 %)
Sambaa 27 (6 %) 4 (7 %) 19 (7 %) 4 (3 %)
Otherb 100 (20 %) 9 (16 %) 59 (21 %) 32 (22 %)
Education 0.35
None 31 (6 %) 4 (7 %) 7 (3 %) 20 (14 %)
Primary 349 (73 %) 40 (70 %) 210 (76 %) 99 (67 %)
Secondary 74 (15 %) 7 (12 %) 47 (17 %) 20 (14 %)
Post–Secondary 27 (6 %) 6 (11 %) 13 (5 %) 8 (5 %)
Occupation <0.01
Unemployed 74 (15 %) 10 (17 %) 47 (17 %) 17 (12 %)
Farmer/Wage Earner 199 (41 %) 14 (25 %) 119 (43 %) 66 (45 %)
Small Business/Vendors 158 (33 %) 21 (37 %) 100 (36 %) 37 (25 %)
Professionalc 50 (10 %) 12 (21 %) 11 (4 %) 27 (18 %)
History of Smoking 117 (24 %) 16 (28 %) 61 (22 %) 40 (27 %) 0.44
History of alcohol intake 318 (66 %) 40 (70 %) 166 (60 %) 112 (76 %) 0.75
Self-Reported Medical History
Hypertension 134 (28 %) 25 (44 %) 51 (19 %) 58 (39 %) <0.01
Diabetes 61 (13 %) 17 (30 %) 15 (5 %) 29 (20 %) <0.01
Heart Diseased 18 (4 %) 6 (11 %) 5 (2 %) 7 (5 %) <0.01
HIV 21 (4 %) 6 (11 %) 5 (2 %) 10 (7 %) 0.02
Stroke 8 (2 %) 2 (4 %) 2 (1 %) 4 (3 %) 0.25
COPD 25 (5 %) 0 (0 %) 4 (1 %) 4 (3 %) 0.30
Kidney Disease 14 (3 %) 6 (11 %) 6 (2 %) 2 (1 %) <0.01
aP-value comparing differences by CKD status (present or absent)
bOther ethnicities includes Maasai, Luguru, Kilindi, Kurya, Mziguwa, Mnyisanzu, Rangi, Jita, Nyambo, and Kaguru
cProfessional included any salaried position (e.g. nurse, teacher, government employee, etc.) and retired persons
dHeart disease included coronary disease, heart failure, or structural diseases
COPD = Chronic obstructive pulmonary disease
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Table 2 Epidemiology and characteristics of traditional medicine (TM) use stratified by CKD and CKD risk status; CKD-AFRIKA (2014)
With CKD; n = 57 CKD Absent; n = 424
(%, 95 % CI) (%, 95 % CI)
Low risk (n = 277) Increased risk (n = 147)
Prevalence
of TM Use 70.3 % (50.0–84.9) 65.3 % (55.2–74.1) 49.0 % (33.1–65.0)
of concurrent TM and Biomedicine Use 33.2 % (11.4–65.6) 4.35 % (2.15–8.61) 10.4 % (4.70–21.6)
Incidence of TM Use (per year)
1–5 times 54.4 % (33.4–73.9) 50.5 % (41.3–59.6) 31.0 % (20.8–43.3)
6–10 times 11.7 % (3.30–33.6) 7.69 % (4.86–12.0) 11.5 % (5.50–22.4)
>10 times 4.30 % (0.01–20.7) 7.07 % (3.78–12.8) 7.10 % (3.60–13.5)
Reasons for TM Use
More Effective 85.4 % (65.3–94.8) 81.3 % (72.4–87.8) 85.3 % (70.1–93.5)
Lower Cost 65.7 % (45.2–81.7) 58.8 % (44.5–71.7) 63.0 % (49.7–74.6)
Easier to Access 58.7 % (39.3–75.6) 66.8 % (58.7–74.0) 72.7 % (58.0–83.7)
Safer 54.9 % (34.3–74.0) 39.5 % (30.0–49.8) 46.0 % (29.1–63.8)
More Traditional/Religious 37.9 % (21.1–58.0) 31.1 % (23.0–40.7) 28.9 % (14.8–48.7)
Modes of Healthcare Access
Medical Doctors 99.4 % (94.8–99.9) 97.7 % (94.0–99.1) 94.7 % (88.4–97.6)
Family and Elders 53.0 % (33.0–72.1) 51.9 % (37.9–65.6) 53.7 % (38.0–68.6)
Traditional Healers 28.7 % (13.8–50.3) 5.10 % (2.03–12.2) 6.81 % (3.03–14.6)
Pharmacists 26.8 % (13.1–47.0) 21.5 % (13.4–32.6) 14.2 % (4.95–34.6)
Herbal Vendors 11.8 % (3.30–34.6) 4.29 % (12.8–13.4) 5.33 % (2.00–13.4)
Friends/Neighbors 10.6 % (4.40–23.3) 17.0 % (11.0–25.4) 17.2 % (8.21–32.6)
TM Use
for Symptomatic Ailments 66.7 % (17.3–54.3) 33.9 % (25.2–43.9) 42.7 % (30.1–56.2)
for Chronic Diseases 49.6 % (28.6–70.6) 25.9 % (17.9–35.8) 26.3 % (14.3–43.4)
for Reproductive Illnesses 45.1 % (23.3–69.1) 19.7 % (11.6–31.3) 16.4 % (8.75–28.5)
for Malaria/Febrile Illnesses 64.0 % (44.1–79.9) 61.9 % (46.9–75.0) 46.8 % (31.4–62.8)
for Spiritual/traditional uses 16.1 % (8.71–27.9) 9.30 % (5.13–16.3) 4.69 % (1.48–13.8)
for Neurologic Illnesses 45.1 % (23.3–69.1) 19.7 % (11.6–31.3) 16.4 % (8.75–28.5)
for Urogenital Conditions 35.3 % (17.7–58.0) 15.8 % (9.39–25.5) 13.4 % (7.56–22.8)
for Cancers 11.1 % (3.86–28.3) 17.8 % (7.87–35.4) 7.64 % (3.16–17.3)
for Disease Prevention 5.17 % (1.75–14.3) 4.66 % (2.24–9.43) 6.99 % (2.77–16.5)
for Worms/Parasites 30.7 % (16.0–50.7) 8.36 % (5.04–13.6) 17.0 % (10.3–26.8)
Modes of TM Use
Mix with water 91.8 % (82.7–96.3) 81.6 % (73.3–87.7) 84.8 % (75.5–91.0)
Drink as a tea 61.6 % (40.8–78.9) 55.5 % (42.6–67.7) 65.9 % (54.9–75.3)
Drink as a soup 59.6 % (39.4–77.0) 42.9 % (32.6–54.4) 47.5 % (37.6–57.5)
Chew from the plant 38.4 % (21.2–59.1) 56.3 % (46.1–66.1) 59.1 % (43.9–72.8)
Drink with milk 33.2 % (15.4–57.5) 20.7 % (14.5–28.5) 24.3 % (16.0–35.1)
Bath 33.5 % (14.6–59.7) 25.5 % (17.8–35.0) 31.8 % (16.8–51.9)
Inhalation 49.3 % (27.7–71.1) 30.2 % (20.0–42.8) 42.4 % (29.7–56.1)
Powders 19.5 % (2.85–48.5) 15.0 % (9.75–22.2) 26.5 % (12.4–47.9)
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biomedicines was high. Community members with CKD
in northern Tanzania frequently sought healthcare ad-
vice from many non-biomedical practitioners including
family members, community and tribal elders, friends,
traditional healers, and herbal vendors. Cost, effective-
ness, access, and safety were reported as common rea-
sons for TM use over or concurrent with biomedicine.
This is consistent with previous studies that have shown
these to be important factors, especially among the
NCDs, for the use of TM in Northern Tanzania [4,5].
The low disease awareness among persons with CKD
implies that the high prevalence of TM use among this
population may reflect their chronically poorer overall
health or their perception of poorer health. Behind daily
symptomatic ailments and malaria/febrile illness, the
prevalence of TM use for chronic diseases was the high-
est which suggests that TM use may also be high for
other NCDs such as diabetes and hypertension. In a re-
gion where CKD and NCD prevalence is high and many
people continue to be at risk for these diseases, further
understanding of TM practices surrounding NCDs will
be important [4].
Separate from the use of TM among persons living
with CKD, we studied the TMs used among the general
population for the treatment of kidney disease. Although
different disease understandings likely meant that what
was called ‘kidney disease’ in a local context was quite
different from the biomedical terms ‘chronic kidney dis-
ease’ or ‘acute kidney injury’ (e.g. urinary tract infections
were frequently referred to as some form of kidney dis-
ease), understanding the TMs used for perceived kidney
disease in any context remains important. Disease preva-
lence is high in the region, and public health programs
aimed at increasing awareness need to be fully informed
about their impact [4]. For example, many of the TMs
used to treat what is perceived as kidney disease in the
region do have pharmacologically active compounds
with a wide-spectrum of effects including lipid-lowering,
anti-microbial, anti-inflammatory, and anti-oxidative ac-
tions. However, we also found that they have multiple
potential adverse effects including diarrhea, volume de-
pletion, increased bleeding risk, hepatotoxicty, and
nephrotoxicity, and these adverse effects may be aug-
mented by the presence of CKD or their concurrent use
with biomedicines. As such, CKD treatment programs
and public health policies aimed at addressing CKD may
have inadvertent consequences for patients and pro-
viders if they do not recognize these practices among
their target populations.
Furthermore, much remains unknown about the
causes of CKD in the region, and cataloguing the re-
gional ethnopharmacology will be important in under-
standing and treating CKD [5]. It is not known to what
extent TM use contributes to the prevalence or progres-
sion of CKD, but plant-based TMs have many mecha-
nisms of nephrotoxicity including renal tubular damage,
hypertension, papillary necrosis, acute tubular necrosis,
interstitial nephritis, and nephrolithiasis [6,7]. We identi-
fied five plant-based TMs used for kidney disease in the
region, two of which have direct potential nephrotoxi-
cities: Aloe vera and Cymbopogon citrullus [10–12]. In
many instances, this nephrotoxicity is dose-dependent,
and this underscores the additional importance of also
understanding the mode by which people consume TMs
because people with CKD may be particularly vulnerable
to these effects. In the case of Aloe vera, which can
cause acute tubular necrosis and acute interstitial neph-
ritis in addition to chronic renal insufficiency, the
nephrotoxicy is substantially higher with the larger doses
ingested by boiling and drinking the plant [10,11].
People with CKD may be particularly vulnerable to ad-
verse effects from TMs, and as such, biomedical clinics
caring for these populations may need to provide direct
education about specific types and modes of TMs to
avoid. As an example, a visual catalogue with pictures of
the various forms of high-risk TMs may be useful as a
guide for patients and providers (both biomedical and
traditional).
Our study has many strengths. To our knowledge, this
is one of few assessments of TM practices among a
community-based, representative sample of participants
with CKD, and because of our random sampling methods,
these prevalence estimates may be generalizable across
the regional population. Additionally, we also were able to
Table 2 Epidemiology and characteristics of traditional medicine (TM) use stratified by CKD and CKD risk status; CKD-AFRIKA (2014)
(Continued)
As foods to be eaten 2.40 % (0.51–10.6) 3.64 % (1.31–9.67) 2.96 % (0.76–10.8)
Pill/Vitamin form 2.59 % (0.60–10.5) 0.63 % (0.19–2.05) 0.85 % (0.20–3.46)
Lotions/Creams 1.21 % (0.26–5.50) 6.05 % (3.06–11.6) 7.81 % (3.10–18.3)
Chronic Diseases: Hypertension, Heart problems, Diabetes, or Body Swelling
Reproductive illnesses: Sexual Arousal/Virility, Menstrual Problems, Pregnancy Termination, or Fertility/Impotence
Neurologic illnesses: Epilepsy, Mental Confusion, or Depression
Spiritual/Traditional: Peace of mind/Ward off curses, Protection from ‘evil eyes’, Unexplained Illnesses, or ‘To Improve Luck’
Symptomatic Ailments: Increase Strength, Constipation, Increase energy, Digestion/Stomach problems, Fatigue, Arthritis/joint pains, Flu/Cold symptoms,
Headaches, or Skin problems
Urogenital: Kidney problems or Urinary problems
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Table 3 Traditional medicines used for the local treatment of kidney diseases in Kilimanjaro Region, Tanzania
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West Africa (Nigeria, Togo, Ivory
Coast): anti-diarrheal,
diabetes/hyperglycemia, anti-
inflammatory, wound healing, anti-
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-Increased risk of bleeding when
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similar to acetylsalicylate and
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vector control, diarrhea, sore throat,
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assess TM use and practices among other community-based
populations at risk for CKD. Finally, the qualitative sessions
provided insight into the use of TMs for the local treatment
of kidney disease and allowed us to explore and identify add-
itional plant-based TMs used for treating kidney disease.
We also noted a few limitations. As this was a cross-
sectional study, causal inferences cannot be drawn and
associations may be influenced by confounding from un-
measured variables. Furthermore, our study may be sub-
ject to non-response bias, and to reduce this potential
bias we used sample-balanced weights when reporting
prevalence estimates. Our study may also have been sub-
ject to reporting and recall bias especially around the
topics on frequencies of TM use. To reduce these biases,
we used only local native surveyors who spoke Swahili
as their first language, conducted the interviews in pri-
vate when possible, and pre-tested the survey instrument
for content validity and design flaws. Misclassification of
disease may also be present, and though we expect most
misclassification to be non-differential, the measurement
we used to diagnose diabetes (HbA1c) has not been vali-
dated in this population. As such, the sensitivity and specifi-
city of the test at a cutoff value of 7.0 % are not known for
this population.
Conclusion
In conclusion, the prevalence of TM use is high among
adults with and at risk for CKD in northern Tanzania,
and many of these same people use biomedicine and
TM concurrently. People with CKD seek healthcare ad-
vice from many sources other than biomedical doctors
such as traditional healers, herbal vendors, and family
members, and they use TMs to treat a variety of condi-
tions including other NCDs. The TMs commonly used
for the local treatment of kidney disease have a wide
range of activities, and people with CKD may be particu-
larly vulnerable to adverse effects. Recognizing these
traditional medicine practices will be important in shap-
ing CKD treatment programs and public health policies
aimed at addressing CKD.
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